Bank of America Boosts Agilent Technologies (NYSE:A) Price Target to $180.00

Agilent Technologies (NYSE:A) had its price objective boosted by stock analysts at Bank of America from $155.00 to $180.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Bank of America‘s target price would indicate a potential upside of 14.49% from the stock’s previous close.

A number of other equities research analysts have also issued reports on A. Morgan Stanley lifted their target price on Agilent Technologies from $160.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Sanford C. Bernstein boosted their price objective on shares of Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Thursday. Royal Bank Of Canada raised their target price on shares of Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday. JPMorgan Chase & Co. boosted their price target on shares of Agilent Technologies from $180.00 to $190.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, TD Cowen raised their price objective on Agilent Technologies from $155.00 to $180.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.33.

Agilent Technologies Stock Up 1.4%

Shares of A stock traded up $2.13 during trading hours on Thursday, hitting $157.22. 1,992,931 shares of the company were exchanged, compared to its average volume of 2,232,849. The company has a market capitalization of $44.40 billion, a PE ratio of 31.56, a PEG ratio of 2.73 and a beta of 1.25. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $163.75. The business has a 50 day moving average of $139.16 and a two-hundred day moving average of $126.65. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.13. The firm had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company’s revenue for the quarter was up 8.1% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Analysts anticipate that Agilent Technologies will post 6.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds have recently added to or reduced their stakes in A. California State Teachers Retirement System boosted its position in Agilent Technologies by 12,343.3% during the second quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock worth $7,249,471,000 after purchasing an additional 54,138,451 shares during the period. Norges Bank acquired a new stake in shares of Agilent Technologies during the 4th quarter worth about $549,158,000. Bank of New York Mellon Corp lifted its stake in shares of Agilent Technologies by 87.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock worth $695,227,000 after buying an additional 2,440,360 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Agilent Technologies during the 2nd quarter worth about $260,101,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Agilent Technologies by 424.1% during the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after buying an additional 1,652,244 shares during the period. Institutional investors and hedge funds own 87.41% of the company’s stock.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.